Skip to main content
Journal cover image

Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.

Publication ,  Conference
Sharma, A; Ambrosy, AP; DeVore, AD; Margulies, KB; McNulty, SE; Mentz, RJ; Hernandez, AF; Michael Felker, G; Cooper, LB; Lala, A; Vader, J ...
Published in: ESC Heart Fail
December 2018

AIMS: Obesity is present in up to 45% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. METHODS AND RESULTS: The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction ≤ 40%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an 'on-treatment' analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61 years, 21% were female, and 69% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25% (25th, 75th percentile 19-32%). Liraglutide use was associated with a significant weight reduction [liraglutide -1.00 lbs vs. placebo 2.00 lbs; treatment difference -4.10 lbs; 95% confidence interval (CI) -7.94, -0.25; P = 0.0367; percentage treatment difference -2.07%, 95% CI -3.86, -0.28; P = 0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5 mg/dL vs. placebo 12.0 mg/dL; treatment difference -33.1 mg/dL; 95% CI -60.7, -5.6; P = 0.019). CONCLUSIONS: Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

ESC Heart Fail

DOI

EISSN

2055-5822

Publication Date

December 2018

Volume

5

Issue

6

Start / End Page

1035 / 1043

Location

England

Related Subject Headings

  • Weight Loss
  • Treatment Outcome
  • Stroke Volume
  • Obesity
  • Middle Aged
  • Male
  • Liraglutide
  • Injections, Subcutaneous
  • Hypoglycemic Agents
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., … Velazquez, E. J. (2018). Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. In ESC Heart Fail (Vol. 5, pp. 1035–1043). England. https://doi.org/10.1002/ehf2.12334
Sharma, Abhinav, Andrew P. Ambrosy, Adam D. DeVore, Kenneth B. Margulies, Steven E. McNulty, Robert J. Mentz, Adrian F. Hernandez, et al. “Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.” In ESC Heart Fail, 5:1035–43, 2018. https://doi.org/10.1002/ehf2.12334.
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, et al. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. In: ESC Heart Fail. 2018. p. 1035–43.
Sharma, Abhinav, et al. “Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial.ESC Heart Fail, vol. 5, no. 6, 2018, pp. 1035–43. Pubmed, doi:10.1002/ehf2.12334.
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Michael Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Fail. 2018. p. 1035–1043.
Journal cover image

Published In

ESC Heart Fail

DOI

EISSN

2055-5822

Publication Date

December 2018

Volume

5

Issue

6

Start / End Page

1035 / 1043

Location

England

Related Subject Headings

  • Weight Loss
  • Treatment Outcome
  • Stroke Volume
  • Obesity
  • Middle Aged
  • Male
  • Liraglutide
  • Injections, Subcutaneous
  • Hypoglycemic Agents
  • Humans